A clinical trial led by Richard S. Hotchkiss, MD, a professor of anesthesiology at WashU Medicine, has found that treating critically ill COVID-19 patients with an immune-boosting protein reduces life-threatening secondary infections, a major cause of death in such patients. The protein is a cytokine, called interleukin-7 (IL-7), naturally produced by the body. The study highlights the potential for IL-7 treatment to improve outcomes among immunocompromised COVID-19 patients.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
